Danuglipron: Uses, Benefits & Research

What is Danuglipron?

Danuglipron (PF-06882961) is an orally bioavailable small-molecule GLP-1 receptor agonist developed by Pfizer. With a molecular weight of approximately 535 Da and molecular formula C26H32F3N5O5, it is fundamentally different from peptide-based GLP-1 drugs like semaglutide, liraglutide, and tirzepatide — it is a small molecule, not a peptide, enabling conventional oral tablet formulation without the absorption challenges that peptide drugs face.

Danuglipron remains investigational with no FDA approval as of March 2026. Pfizer is transitioning from an earlier twice-daily formulation to a once-daily version designed to improve tolerability.

Mechanism of Action

Danuglipron activates the GLP-1 receptor (GLP-1R) with selectivity, mimicking the action of endogenous GLP-1 through four downstream effects:

• Glucose-dependent insulin secretion — stimulates pancreatic beta cells to release insulin only when blood glucose is elevated
• Glucagon suppression — reduces hepatic glucose output
• Gastric emptying delay — slows nutrient absorption, contributing to satiety
• Appetite reduction — central nervous system effects reduce food intake

As a small molecule, danuglipron achieves oral bioavailability through molecular design rather than the fatty acid conjugation or absorption enhancers required by peptide GLP-1 drugs. This enables conventional oral tablet manufacturing.

Clinical Evidence

Human Studies

• Phase 2b obesity trial (NCT04707313): 610 adults with BMI ≥30 (or ≥27 with comorbidity) randomized to multiple dose groups vs placebo for 32 weeks. Mean placebo-adjusted weight reductions of 8% to 13% at 32 weeks. GI adverse events were mild and consistent with GLP-1 class.
• Phase 2 T2D trial (NCT04034303): 411 adults with Type 2 diabetes showed significant improvements in glycemic control with concurrent weight reduction.
• Dose-optimization studies (NCT06567327, NCT06568731): Completed PK studies of once-daily formulation across 1,400+ participants. No observed increase in liver enzymes. Pfizer reported the formulation met objectives for “competitive efficacy and tolerability profile in Phase 3 testing.”

Preclinical

Danuglipron advanced to clinical trials based on in vitro GLP-1R binding studies and the novelty of the oral small-molecule approach. Detailed preclinical data has not been publicly cited.

Drug Interactions & Contraindications

No formal human drug interaction studies have been published. Theoretical interactions derive from the GLP-1 receptor agonist class:

• Oral medications: Delayed gastric emptying may affect absorption timing of concurrent oral drugs
• Insulin/sulfonylureas: Additive hypoglycemic risk — dose adjustment may be needed
• Oral contraceptives: Potential reduced absorption due to delayed gastric emptying

Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 (GLP-1 class precaution based on rodent data). No data for pregnancy or pediatric populations.

Safety & Side Effects

The safety profile is consistent with the GLP-1 receptor agonist class. Most common adverse events are gastrointestinal: nausea (dose-dependent), diarrhea, vomiting, constipation, and headache. No new safety signals emerged in Phase 2b testing. Notably, no liver enzyme elevations were observed across 1,400+ participants in dose-optimization studies.

The transition from twice-daily to once-daily formulation was driven by the earlier formulation’s higher GI adverse event rates. Theoretical class-effect risks include gastroparesis, pancreatitis, and thyroid C-cell tumors (seen in rodents, not confirmed in humans).

Honest Bottom Line

Danuglipron is a promising oral small-molecule GLP-1 receptor agonist that demonstrated meaningful weight loss (8-13% placebo-adjusted at 32 weeks) in Phase 2b trials. As an oral tablet rather than an injection, it addresses a significant barrier to GLP-1 therapy adoption. However, it remains investigational with no FDA approval, and its evidence base (~5-8 RCTs) is modest compared to established GLP-1 peptides. The once-daily reformulation may improve tolerability, but Phase 3 data and regulatory approval are needed. Patients seeking oral GLP-1 options should discuss approved alternatives with their providers while monitoring danuglipron’s development timeline.